NCT05475665View on ClinicalTrials.gov

Clinical Efficacy and Safety Evaluation of Irbesartan High and Amlodipine Combined Therapy in Essential Hypertension Patients

PHASE3CompletedINTERVENTIONAL
Enrollment

157

Participants

Timeline

Start Date

July 14, 2022

Primary Completion Date

March 30, 2023

Study Completion Date

June 13, 2023

Conditions
Essential Hypertension
Interventions
DRUG

Irbesartan/Amlodipine

Irbesartan/Amlodipine once daily for 8 weeks

DRUG

Irbesartan

Irbesartan once daily for 8 weeks

Trial Locations (1)

Unknown

Hanyang University Seoul Hospital, Seoul

Sponsors

Lead Sponsor

Handok Inc.
All Listed Sponsors
lead

Handok Inc.

INDUSTRY